1235545-49-9

Upstream product

• 1109284-47-0 tert-butyl [(1R,6S)-6-amino-2,2-difluorocyclohexyl]carbamate 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 

Downstream Products

• 1235545-48-8 (1R,6S)-6-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-2,2-difluorocyclohexanaminium chloride 
• 1314893-30-5 N-[(1R,6S)-6-amino-2,2-difluorocyclohexyl]-4-(6-chloropyrazolo[1,5-a]pyrimidin-3-yl)-5-ethylthiophene-2-carboxamide 
• 1314893-34-9 N-[(1R,6S)-6-amino-2,2-difluorocyclohexyl]-5-ethyl-4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl)thiophene-2-carboxamide 

Relevant academic research and scientific papers

PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS

The invention encompasses pyrazolo[1,5-a]pyrimidine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.

IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS

The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.